Summit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual Meeting
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: GlobeNewswire
OXFORD, United Kingdom and CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces that it has been selected for an Emerging Science dual oral and poster presentation at the 2018 American Academy of Neurology Annual Meeting taking place 21-27 April 2018 in Los Angeles, CA, US. These late-breaking presentations will feature the interim 24-week data from the PhaseOut DMD clinical trial. Details of the presentations: Abstract Title: Ezutromid significantly reduced muscle damage whilst maintaining utrophin in patients with Duchenne muscular dystrophy (DMD) after 24-weeks of treatmentAuthors: Francesco Muntoni, Gary Layton, Indranil Bhattacharya, Crystal Faelan, Anne C Heatherington, David Roblin, Jon Tinsley, PhaseOut DMD Study Group and Kay E DaviesSession: Emerging ScienceSession Date/Time: Tuesday, 24 April 2018, 5:45-7:00pm PDT; Data Blitz presentation at 6:03pm PDT About Summit Therapeutics Summit is a biopharmaceutical com
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Akeso Marks Profit Milestone With Swift Rights Issue [Seeking Alpha]Seeking Alpha
- Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
- Summit Therapeutics Insiders Up US$5.1m On US$5.05m Investment [Yahoo! Finance]Yahoo! Finance
- China Powerwoman's Akeso Raises $150 Mln After First Profit [Forbes]Forbes
- Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 [Yahoo! Finance]Yahoo! Finance
SMMT
Sec Filings
- 3/27/24 - Form 4
- 3/27/24 - Form 4
- 3/22/24 - Form 8-K
- SMMT's page on the SEC website